Pharma Report 2016

Spending on drugs is up, but by how much?

Total medicine spending surged to $424.8 billion in 2015, representing an increase of 12.2%. Here's why that growth figure is closer to 2.9%.

2016 Pharma Report: All the data in one place

Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.

2016 Pharma Report: Index of top 20 drugmakers

The index of the top 20 drugmakers from the 2016 pharma report.

1. Gilead Sciences

Gilead's current and future success lies in the hands of its antiviral franchise.

2. Johnson & Johnson

J&J has earmarked a pile of cash — in the neighborhood of $18.5 billion — for future acquisition targets, but is patiently pacing the sidelines for the best players to walk onto the field.

3. Merck

Merck's landmark approval in 2015 was for immunotherapy Keytruda, which was cleared in October as a second-line treatment for the most common form of skin cancer.

4. Novartis

There are two primary reasons Novartis anticipates flat sales during 2016: Its hallmark cancer drug Gleevec recently came off patent and its Alcon ophthalmic business has seen declining growth rates.

5. Pfizer

Pfizer's dream to shave the top off a rising U.S. tax bill — and level the playing field with overseas competitors — was dashed.

6. AstraZeneca

AstraZeneca has embarked on what's likely to be a long, rough ride.

7. Teva

Analysts agree that Teva is casting a healthy financial shadow.

8. Amgen

As Amgen executives continue to toast a spectacular 2015 performance — double-digit growth from five of eight blockbusters — CEO Robert Bradway has cast a keen eye on the biotech pioneer's future.

9. Roche

On the sales and profit forecast front, analysts say that Roche missed the mark in 2015.

10. Sanofi

The big news: Sanofi and its partner Regeneron received approval for the first PCSK9 inhibitor to come to market in the U.S.: Praluent. But Praluent's sales to date haven't awed analysts.

11. Allergan

Allergan and Pfizer agreed to scrap their pending mega-merger following an early April power play by the U.S. government.

12. AbbVie

Coming off what AbbVie's board dubbed an "exceptional year," 2016 may sting.

13. Eli Lilly

Diabetes drugs headlined Eli Lilly's 2015 results, with Humalog and Trulicity contributing mightily to the upward sales curve.

14. Novo Nordisk

Novo Nordisk wants to own the obesity space much in the same way that it has attempted to dominate diabetes.

15. GlaxoSmithKline

The year 2015 was one of restructuring for GlaxoSmithKline.

16. Boehringer Ingelheim

In an effort to overcome pricing pressures and bounce back from patent losses, Germany's second-largest drugmaker has unloaded assets and reshuffled its management team.

17. Mylan

After turning its back on an offer from generics competitor Teva, Mylan stepped up with an unsuccessful hostile takeover bid for generic drugmaker Perrigo.

18. Biogen

Biogen's 2015 was hindered by less-than-stellar sales of its flagship multiple sclerosis treatment Tecfidera.

19. Valeant

So, heard anything lately about Valeant? Yeah. Even by the standards of an industry under siege, Valeant experienced quite the tumultuous last year or so.

20. Bristol-Myers Squibb

Immuno-oncology was the story at Bristol-Myers Squibb in 2015.